Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q2 2018 · 10-Q
Revenue$5.65B$5.65B−20.9% vs Q2 2017 Net Income$1.82B$1.82B−40.9% vs Q2 2017 EPS Diluted$1.39$1.39−40.3% vs Q2 2017 Gross Profit$4,344,000,000−26.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,573,000,000−55.4% Free Cash Flowderived$1,276,000,000−62.5% Margins · derivedGross margin76.9%−6.0 pt vs Q2 2017
Operating margin40.4%−19.2 pt vs Q2 2017
Net margin32.2%−10.9 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 6, 2018 · 37 d after period end